Cargando…

Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes

OBJECTIVE: Hyperglycemia and hypoglycemia currently are considered risk factors for cardiovascular disease in type 1diabetes. Both acute hyperglycemia and hypoglycemia induce endothelial dysfunction and inflammation, raising the oxidative stress. Glucagon-like peptide 1 (GLP-1) has antioxidant prope...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceriello, Antonio, Novials, Anna, Ortega, Emilio, Canivell, Silvia, La Sala, Lucia, Pujadas, Gemma, Esposito, Katherine, Giugliano, Dario, Genovese, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714509/ https://www.ncbi.nlm.nih.gov/pubmed/23564922 http://dx.doi.org/10.2337/dc12-2469

Ejemplares similares

Vitamin C Further Improves the Protective Effect of Glucagon-Like Peptide-1 on Acute Hypoglycemia-Induced Oxidative Stress, Inflammation, and Endothelial Dysfunction in Type 1 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2013)

Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2013)

Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2012)

GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress
por: Ceriello, Antonio, et al.
Publicado: (2015)

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2011)

The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report
por: Ceriello, Antonio, et al.
Publicado: (2014)

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
por: Pujadas, Gemma, et al.
Publicado: (2016)

Short-term high glucose exposure impairs insulin signaling in endothelial cells
por: De Nigris, Valeria, et al.
Publicado: (2015)

Cardiovascular guidelines: separate career may help attenuate controversy
por: Esposito, Katherine, et al.
Publicado: (2014)

Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells
por: La Sala, Lucia, et al.
Publicado: (2016)

Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions
por: De Nigris, Valeria, et al.
Publicado: (2017)

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
por: Uccellatore, Annachiara, et al.
Publicado: (2015)

Glucagon and heart in type 2 diabetes: new perspectives
por: Ceriello, Antonio, et al.
Publicado: (2016)

Cardiovascular Importance of Hyperglycemia and Hypoglycemia
por: Tkáč, Ivan
Publicado: (2013)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?
por: Prattichizzo, F., et al.
Publicado: (2016)

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
por: Siafarikas, Aris, et al.
Publicado: (2012)

Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia
por: Pontiroli, Antonio E., et al.
Publicado: (2019)

Why Glucagon Matters for Hypoglycemia and Physical Activity in Individuals With Type 1 Diabetes
por: Colberg, Sheri R.
Publicado: (2022)

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
por: Tan, Tricia M., et al.
Publicado: (2013)

Comment on: Raz et al. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2013;36:1779–1788
por: Giugliano, Dario, et al.
Publicado: (2013)

Efficacy of Insulin Analogs in Achieving the Hemoglobin A(1c) Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Giugliano, Dario, et al.
Publicado: (2011)

Hypoglycemia and hyperglycemia in extremely low-birth-weight infants
por: De Carolis, Maria Pia, et al.
Publicado: (2015)

Olfactory marker protein regulation of glucagon secretion in hyperglycemia
por: Oh, Ju Hun, et al.
Publicado: (2022)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia, Nitil
Publicado: (2011)

Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
por: Castle, Jessica R., et al.
Publicado: (2010)

Severe Hypoglycemia and the Use of Glucagon Rescue Agents: An Observational Survey in Adults With Type 1 Diabetes
por: Hughes, Allyson S., et al.
Publicado: (2023)

Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes
por: Funk, Steven Daniel, et al.
Publicado: (2012)

New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions
por: La Sala, Lucia, et al.
Publicado: (2021)

Post-Bariatric Hypoglycemia Is Associated with Endothelial Dysfunction and Increased Oxidative Stress
por: Lupoli, Roberta, et al.
Publicado: (2022)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Management of hyperglycemia in type 2 diabetes: evidence and uncertainty
por: Esposito, Katherine, et al.
Publicado: (2013)

The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications
por: Testa, Roberto, et al.
Publicado: (2017)

Hyperglycemia and COVID-19: What was known and what is really new?
por: Ceriello, Antonio
Publicado: (2020)

An Evaluation of Glucagon Injection Anxiety and Its Association with the Fear of Hypoglycemia among the Parents of Children with Type 1 Diabetes
por: Muradoğlu, Serra, et al.
Publicado: (2021)

Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice
por: Zhong, Ying, et al.
Publicado: (2020)

An unusual presentation of post gastric bypass hypoglycemia with both postprandial and fasting hypoglycemia
por: Chen, Xin, et al.
Publicado: (2018)

Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?
por: Ceriello, Antonio
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_o2l8vr9chdc16cnc8qa54aff3b